Therefore, alantolactone combined MAPKi could dual suppress STAT3 and BRAF/MEK/ERK1/2 pathways, consequently inhibiting the expression of downstream Klf4, Oct4, Sox2 and c-Myc proteins, to enhance sensitivity of resistant melanoma to MAPKi. Here, SOX2 is linked to melanoma.